ArticleArteriosclerosis, thrombosis, and vascular biology2011
Angiotensin-converting enzyme 2 deficiency in whole body or bone marrow-derived cells increases atherosclerosis in low-density lipoprotein receptor-/- mice.
Article in Arteriosclerosis, thrombosis, and vascular biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 80 citations in OpenAlex.
- ELABELA Ameliorates Atherosclerosis Through Restoring the M1/M2 Macrophage Balance inJournal of the American Heart Association · 2025Article
- Reversal of aging-associated increase in myelopoiesis and expression of alarmins by angiotensin-(1-7).Scientific reports · 2023Article
- Plasma Angiotensin Converting Enzyme 2 (ACE2) Activity in Healthy Controls and Patients with Cardiovascular Risk Factors and/or Disease.Journal of personalized medicine · 2022Article
- Bone Marrow Origin of Coronary Artery Diseases: The Impact of the Local Renin-Angiotensin System.Acta Cardiologica Sinica · 2022Review
- Immune and inflammatory mechanisms of abdominal aortic aneurysm.Frontiers in immunology · 2022Review
- Alternative RAS in Various Hypoxic Conditions: From Myocardial Infarction to COVID-19.International journal of molecular sciences · 2021Review
- The impact of the hypoxia-VEGF-vascular permeability on COVID-19-infected patients.Exploration (Beijing, China) · 2021Article
- The SARS-CoV-2/Receptor Axis in Heart and Blood Vessels: A Crisp Update on COVID-19 Disease with Cardiovascular Complications.Viruses · 2021Review
- Male bias in ACE2 basic science research: missed opportunity for discovery in the time of COVID-19.American journal of physiology. Regulatory, integrative and comparative physiology · 2021Review
- Diminazene Aceturate Stabilizes Atherosclerotic Plaque and Attenuates Hepatic Steatosis in apoE-Knockout Mice by Influencing Macrophages Polarization and Taurine Biosynthesis.International journal of molecular sciences · 2021Article
- ACE2 Is an Adjacent Element of Atherosclerosis and COVID-19 Pathogenesis.International journal of molecular sciences · 2021Review
- The Renin-Angiotensin-Aldosterone System and Coronavirus Disease 2019.European cardiology · 2021Review
- Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization.Pathogens (Basel, Switzerland) · 2021Review
- SARS-CoV-2 and endothelial cell interaction in COVID-19: molecular perspectives.Vascular biology (Bristol, England) · 2021Review
- Twenty years of progress in angiotensin converting enzyme 2 and its link to SARS-CoV-2 disease.Clinical science (London, England : 1979) · 2020Review
- ACE2 mouse models: a toolbox for cardiovascular and pulmonary research.Nature communications · 2020Review
- Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications.Life sciences · 2020Review
- Role of Renin-Angiotensin System Components in Atherosclerosis: Focus on Ang-II, ACE2, and Ang-1-7.Frontiers in physiology · 2020Review
- Mas receptor deficiency augments angiotensin II-induced atherosclerosis and aortic aneurysm ruptures in hypercholesterolemic male mice.Journal of vascular surgery · 2019Article
- Renin-Angiotensin System and Cardiovascular Functions.Arteriosclerosis, thrombosis, and vascular biology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
objectiveThe renin-angiotensin system contributes to atherosclerotic lesion formation. Angiotensin-converting enzyme 2 (ACE2) catabolizes angiotensin II (Ang II) to angiotensin 1-7 (Ang-(1-7)) to limit effects of the renin-angiotensin system. The purpose of this study was to define the role of ACE2 in atherosclerosis. METHODS AND
resultsMale Ace2(-/y) mice in an low-density lipoprotein receptor-deficient background were fed a high-fat diet for 3 months. ACE2 deficiency increased atherosclerotic area (Ace2(+/y), 17 ± 1; Ace2(-/y), 23 ± 2 mm(2), P < 0.002). This increase was blunted by losartan. To determine whether leukocytic ACE2 influenced atherosclerosis, irradiated low-density lipoprotein receptor-deficient male mice were repopulated with bone marrow-derived cells from Ace2(+/y) or Ace2(-/y) mice and fed a high-fat diet for 3 months. ACE2 deficiency in bone marrow-derived cells increased atherosclerotic area (Ace2(+/y), 1.6 ± 0.3; Ace2(-/y), 2.8 ± 0.3 mm(2); P < 0.05). Macrophages from Ace2(-/y) mice exhibited increased Ang II secretion and elevated expression of inflammatory cytokines. Conditioned media from mouse peritoneal macrophages of Ace2(-/y) mice increased monocyte adhesion to human umbilical vein endothelial cells. Incubation of human umbilical vein endothelial cells with Ang II promoted monocyte adhesion, which was blocked by Ang-(1-7). Coinfusion of Ang-(1-7) with Ang II reduced atherosclerosis.
conclusionsThese results demonstrate that ACE2 deficiency in bone marrow-derived cells promotes atherosclerosis through regulation of Ang II/Ang-(1-7) peptides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.